Sleeve vs Bypass: How the Decision Actually Gets Made

There are two operations that account for the overwhelming majority of bariatric surgery worldwide: the sleeve gastrectomy and the Roux-en-Y gastric bypass. Patients tend to research them the way you'd research two cars — reading reviews, collecting opinions, forming a preference. Surgeons don't work that way. They run a short sequence of clinical questions, and by the end of it the answer is usually obvious.

This piece walks through that sequence. Not so you can self-prescribe — you can't, and any clinic that lets you is a clinic to walk away from — but so that when a surgeon tells you which operation they'd do, you can tell whether they reasoned their way there or just defaulted to whatever they do most.

Question one: do you have reflux?

This is the first question a good surgeon asks, and it is frequently decisive on its own.

The sleeve creates a high-pressure tube out of a low-pressure sac. In a meaningful minority of patients, that worsens gastro-oesophageal reflux, and in some it creates it where none existed. A bypass does the opposite: it diverts acid away from the oesophagus, and it is the standard operation offered to patients whose sleeve later gives them intractable reflux.

So: if you have significant reflux now, most surgeons will steer you away from a sleeve. If you have Barrett's oesophagus — a change in the lining of the lower oesophagus caused by chronic acid exposure — a sleeve is generally considered contraindicated outright. If you have a large hiatal hernia, that gets repaired at the same operation, and its size and character will feed into the choice.

Question two: do you have type 2 diabetes, and how established is it?

Both operations improve type 2 diabetes, and both often do it before you've lost meaningful weight — which tells you the mechanism isn't simply the weight loss. The bypass, though, has the stronger and more durable track record, particularly in patients who have had diabetes for a long time or who are already on insulin.

The rough clinical heuristic most teams use: shorter duration of diabetes, still oral-medication-controlled, decent remaining pancreatic function — either operation is reasonable. Longer duration, insulin-dependent, harder to control — the case for bypass strengthens considerably.

Other metabolic comorbidities pull in the same direction. Severe dyslipidaemia and severe obstructive sleep apnoea both tend to favour the more powerful operation.

Question three: what's your starting BMI, and what's the target?

At very high BMI — the numbers usually discussed are in the 50-plus range — the sleeve sometimes gets chosen as a first stage rather than a final answer. It's a shorter, lower-risk operation to perform on a patient in whom every extra minute of anaesthesia carries weight, and it can be converted to a bypass or a duodenal switch later once the patient has lost enough to make the second operation safer.

That staged approach is a legitimate plan. What it is not is a surprise. If your surgeon is thinking of the sleeve as stage one of two, that needs to be said out loud, in writing, before you agree to anything — because a two-stage plan across an international border is a materially different proposition from a one-and-done trip.

Question four: what do you take, and what will you need to take?

Bypass changes absorption. That is the whole point, and it's also the catch. Extended-release medications, some psychiatric medications, and iron and calcium in particular behave differently after a bypass. Non-steroidal anti-inflammatories — ibuprofen, naproxen, the whole class — are generally off the table for life after a bypass because of marginal ulcer risk, which matters enormously if you have chronic joint pain and have been living on them.

Patients with inflammatory bowel disease, extensive prior abdominal surgery, or a transplant history on immunosuppression are usually steered toward the sleeve for the same family of reasons: fewer variables, less rerouting, easier to scope and investigate later.

The operations nobody mentions

Sleeve and bypass dominate, but they aren't the whole menu.

• Duodenal switch (BPD/DS) and SADI-S. The most powerful options, generally reserved for very high BMI or as revisions. They also carry the highest nutritional burden — the deficiency risk is a different order of magnitude, and the follow-up requirement is non-negotiable. Reasonable for the right patient with the right support structure; a poor fit for someone who will be a plane ride away from their surgical team.
• Adjustable gastric band. Largely abandoned. High reoperation and removal rates over time. If a clinic is still pushing bands in 2026, ask why.
• Endoscopic sleeve gastroplasty. No incisions, no tissue removed — the stomach is sutured into a tube from the inside. Less weight loss than a surgical sleeve, but reversible-ish and lower risk. Legitimate for a narrower group of patients.
• GLP-1 medication instead of surgery. A real option now, and an honest surgeon will say so. It's also a permanent monthly cost, and weight tends to return when it's stopped. Some patients use it before surgery to reduce operative risk; some use it after to address regain. It is not a reason to avoid a surgical consult — it's a reason to have one, so you can compare properly.

What both operations cost

The price gap between the two operations is real but small compared with the price gap between countries. That's worth stating plainly, because it removes cost from the sleeve-versus-bypass decision almost entirely. If a Colombian team recommends a bypass and you were budgeting for a sleeve, the difference is a couple of thousand dollars — which is not a reason to have the wrong operation.

Where cost should influence your thinking is in the total landed number, including the follow-up you'll be paying for over the following decade. We take that apart in the hidden costs piece, and it's the number that actually matters.

Red flags in how the recommendation is delivered

• The operation was picked before the workup. If a price quote for a specific procedure arrives before your endoscopy and labs, the clinical reasoning is decorative.
• Every patient gets a sleeve. Sleeve is the more common operation globally, and there are good reasons for that. But a practice with a 100% sleeve rate is telling you something about its capabilities, not about its patients.
• Reflux gets waved off. "We'll just give you omeprazole" is not a plan for a patient with erosive disease.
• Nobody has mentioned what happens afterwards. A surgeon who discusses the operation but not the ten years after it is selling a procedure, not treating a disease.

The operation is one day. The condition it treats is chronic and lifelong. Choose the surgeon who talks about both.

Where Colombia fits

Colombia is not the highest-volume bariatric destination in Latin America — Mexico is, by a wide margin, and we say so plainly rather than pretending otherwise. What Colombia offers is a deep accredited-hospital layer, surgical teams that operate inside full hospitals rather than standalone clinics, and a comparatively strong culture of multidisciplinary workup. For a patient whose case has any complexity — established diabetes, prior abdominal surgery, a revision question, a high BMI — that hospital context matters more than raw case volume.

It also matters for what comes next. Substantial weight loss leaves loose skin, and Colombia's body contouring depth is genuinely world-class — which is why a lot of patients end up planning a second trip through ColombiaCosmeticSurgery.com eighteen months down the road. For a broader look at how Colombia compares across specialties, the network hub at ColombiaMedical.co covers the rest.

Next: what a proper workup actually involves, and how to tell whether the one you're being offered is real.